Nuritas unveils AI-powered peptide ingredient that improves all stages of sleep

Nuritas has launched PeptiSleep, a natural plant peptide ingredient derived from rice bran protein that supports all stages of sleep by reducing cortisol, a hormone responsible for stress and poor sleep. 

A pilot study using smart rings with sensors that measure biometrics indicates that 61% of participants fell asleep faster. In addition, people using PeptiSleep instead of a placebo experienced an increase of 17% in deep sleep, 13% in light sleep, and an average of 35 minutes of total sleep while also improving readiness and sleep scores. 

Nutrition Insight meets with Dr. Andy Franklyn-Miller, the company’s chief medical and innovation officer, to discuss the new ingredient and its development through Nuritas’ AI-powered Magnifier platform. 

“If we were to try to identify the peptides that work within PeptiSleep by trial and error, it could take us 25 years,” says Franklyn-Miller. “AI has enabled us to pick a receptor, identify a peptide that will match that receptor to work, and then identify that from a library of over nine million plant peptides.” 

“The accuracy of that is about 80%, and that’s unheard of. We’re able to do that because we can use a combination of generative modeling — we can take how that peptide might look, how similar peptides might look, and then predict how they’ll respond.” 

While PeptiSleep supports people across all stages of sleep, Franklyn-Miller says that melatonin, one of the most well-known over-the-counter sleep aids, mainly helps people fall asleep. 

“Often, you get grogginess in the morning. It disrupts your day-to-day rhythm, and the effect wears off over time. But there’s also a dependency. You need more and more melatonin to get the same effect. With PeptiSleep, we’ve seen no dependency effects, and it works from day one.”

In addition, the company feeds biological data on ingredients’ absorption into the platform, which AI extrapolates to get an accurate picture of ingredients’ interactions in the digestive system. 

Dr. Andy Franklyn-Miller, chief medical and innovation officer at Nuritas.Sleep cycles

Franklyn-Miller explains that PeptiSleep suppresses the release of cortisol, a stress hormone responsible for sleep. 

He details: “As we wake up, cortisol rises through the middle of the day and then starts to taper off toward the end of the day. Melatonin is produced by the pineal gland in the brain, which does the same, but in the evening, as cortisol drops off, melatonin increases and then falls off in the morning.” 

“We target the orexin receptor at the adrenal cortex, at the kidney, which works peripherally, and we block that with a peptide to lower cortisol release,” says Franklyn-Miller. “When we look at cortisol in the morning, it’s back to normal levels.”

He adds that PeptiSleep manages the whole of sleep by affecting cortisol rather than only helping consumers fall asleep like melatonin. 

“Cortisol is a stress hormone — if someone’s about to hit us on the head with a club, our heart rate variability narrows, we become tense, and cortisol goes up,” says Franklyn-Miller. “We lead pretty stressful lives, are busy, and don’t get enough sleep.” 

“By lowering cortisol, we improve heart rate variability, that parasympathetic nervous activity, and we relax,” he explains. 

Clinical testing

Nuritas used a sleep evaluation questionnaire in its PeptiSleep clinical trial. Franklyn-Miller says this questionnaire divides sleep into four phases — getting to sleep, sleep quality, behavior in and around waking, and how people feel in the morning after waking. 

“Peptisleep has improved sleep in every one of those quadrants, getting to sleep, quality of sleep, and morning behavior.” 

The clinical trial also used wearables. The 60 healthy participants with mild to moderate sleep impairment wore a ring during the 10-week study, which measured sleep quality, quantity, and heart rate variability. 

Nuritas presented PeptiSleep at the recent Natural Products Expo West trade show.The participants were divided into four groups. Before bed, they consumed 250 mg, 500 mg, or 1,000 mg of PeptiSleep or a placebo (500 mg of microcrystalline cellulose). 

“One of the most exciting things about this study is the use of wearables,” says Franklyn-Miller. He says that while it is common practice to use validated sleep questionnaires, the wearables can demonstrate the ingredient’s effectiveness. 

“Seeing the effectiveness and impact of an ingredient in a wearable is really important to Nuritas. What we saw very clearly was that we improved total sleep, readiness, sleep quality, deep sleep, and rapid eye movement sleep, which fits with the clinical trial data very well in the subject of the questionnaires.”

Franklyn-Miller highlights that almost two-thirds of US citizens have trouble sleeping, and about 40% of people track their sleep with wearable technology. “The challenge is, what do you do? Sleep hygiene is the only normal intervention. Take away screens in a dark room, have the temperature rise, but if you can’t do anything else, that’s a challenge.” 

AI-powered product development

Earlier this year, Nutrition Insight met with Nuritas’ founder and CEO to examine how AI revolutionizes nutrition by merging technology with nature. Dr. Nora Khaldi told us she expects AI-driven ingredient discovery to address more consumer health needs, where AI can create more effective, sustainable, and transparent food and supplements. 

Franklyn-Miller says that Nuritas has multiple lines of business and aims to improve people’s health through its peptide products. 

“We’ve started with muscle health with PeptiStrong. We’re now looking at sleep because it has an impact on health. If we improve the length of time to go to sleep, if we shorten that, you can make a 5% impact in all-cause mortality.” 

“Our next ingredient to come later in the year, PeptiControl, looks at glucose metabolism and managing the glucose spike, being able to change a product from more high GI to more low GI, opening up opportunities. And we’ve got other products in the pipeline regarding gut health, cholesterol management, bone, female health, specifically, and cognition.”